Conference Coverage

Highlights From the 30th Congress of ISTH

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Anna Sternberg, PhD
WATCH
Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Johnny Mahlangu, BSc, MBBCh, MMed, FCPath
WATCH
Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Guy Young, MD
WATCH
Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

Steven W. Pipe, M
WATCH
Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL